Ginkgo Biloba Benefits, Dosage & Evidence: Cognition, Circulation & Aging
Evidence-based guide to Ginkgo biloba (EGb 761) for memory, cerebral blood flow, and cognitive aging. Covers dosage (120-240mg), the GEM trial findings, safety, and what the research actually shows.
The bottom line: Ginkgo biloba (EGb 761 extract) improves cerebral blood flow and shows modest benefits for cognitive function in dementia and age-related cognitive decline. It does not prevent dementia in healthy older adults — the large GEM trial showed no preventive effect. Evidence grade: Moderate for treating cognitive symptoms; negative for prevention in healthy populations.
At a Glance
Ginkgo biloba is one of the oldest living tree species and one of the most prescribed botanical medicines worldwide. Standardized EGb 761 extract (24% flavone glycosides, 6% terpene lactones) is approved in Germany and France for dementia and circulatory disorders.
This table scrolls horizontally on small screens. Use Tab to focus the table region, then scroll with arrow keys or touch.
| Question | Answer |
|---|---|
| Best fit | Age-related cognitive decline, vascular dementia, intermittent claudication |
| Evidence level | Moderate for treating cognitive symptoms; does NOT prevent dementia |
| Typical dose | 120–240 mg/day EGb 761, split into 2–3 doses |
| Onset | 4–12 weeks for cognitive effects |
| Key mechanism | Increases cerebral blood flow, antioxidant, mild antiplatelet |
| Main caution | Blood thinners — theoretical bleeding risk; stop 2 weeks before surgery |
What to Expect
Ginkgo is a marathon supplement, not a sprint. It doesn't produce acute cognitive enhancement like caffeine.
This table scrolls horizontally on small screens. Use Tab to focus the table region, then scroll with arrow keys or touch.
| Timeframe | What you might notice |
|---|---|
| Week 1–4 | Generally nothing noticeable. Blood flow improvements begin but aren't subjectively felt. |
| Week 4–12 | Modest improvements in memory, attention, and mental clarity — mainly in older adults with existing cognitive complaints. |
| Month 3+ | Effects stabilize. If no benefit by 12 weeks, ginkgo is unlikely to help. |
Important reality check: The 3,069-person GEM trial (2008) found ginkgo did NOT reduce dementia incidence in healthy older adults over 6 years. Ginkgo treats symptoms — it doesn't prevent disease. Don't take it expecting to "Alzheimer's-proof" your brain.
Dosage and Forms
Standardized extract
The clinically studied form is EGb 761 — standardized to:
- 24% flavone glycosides
- 6% terpene lactones (ginkgolides + bilobalide)
Dose: 120–240 mg/day, split into 2–3 doses with meals. Start at 120 mg/day and increase after 2–3 weeks if tolerated.
Quality matters
Cheap, unstandardized ginkgo products may contain ginkgolic acids — allergenic compounds that should be removed during extraction. EGb 761 limits ginkgolic acids to <5 ppm. Look for products that explicitly reference EGb 761 standardization or clearly state ginkgolic acid limits.
The Clinical Evidence
Key finding: Ginkgo shows the most consistent benefits in people who already have cognitive impairment — not in healthy people trying to prevent it.
This table scrolls horizontally on small screens. Use Tab to focus the table region, then scroll with arrow keys or touch.
| Study | Population | n | Duration | Dose | Outcome |
|---|---|---|---|---|---|
| GEM Trial 2008 | Healthy elderly, no cognitive impairment | 3,069 | 6 years | 240 mg/day | No reduction in dementia incidence |
| GEM subgroup 2009 | MCI subgroup | ~500 | 6 years | 240 mg/day | Modest cognitive decline slowing in subgroup with MCI |
| Napryeyenko 2007 | Alzheimer's/vascular dementia | 400 | 22 weeks | 240 mg/day | Cognitive scores ↑, caregiver burden ↓ |
| Pittler 2000 | Intermittent claudication | Meta-analysis | — | 120–160 mg/day | Pain-free walking distance ↑ by ~33 meters |
The GEM Trial: what everyone should know
The Ginkgo Evaluation of Memory (GEM) study was the definitive prevention trial: 3,069 cognitively healthy adults aged 75+ took 240 mg/day EGb 761 or placebo for a median of 6.1 years. Result: no significant difference in dementia or Alzheimer's rates between groups.
This doesn't mean ginkgo is useless — it means it's not a preventive. The same trial's subgroup analysis found modest benefits in people who already had mild cognitive impairment (MCI). Think of it as a treatment, not a vaccine.
How It Works (For the Curious)
Ginkgo's effects come from two compound classes in EGb 761 extract:
1. Flavone glycosides (24%) — potent antioxidants that scavenge free radicals and protect neuronal membranes from oxidative damage. This is the primary mechanism for neuroprotection.
2. Terpene lactones (6%) — ginkgolides and bilobalide. Ginkgolide B is a platelet-activating factor (PAF) antagonist, producing mild antiplatelet effects. Bilobalide supports mitochondrial function and has neuroprotective properties.
The combined effect: increased cerebral blood flow + antioxidant protection + mild blood-thinning. This is why ginkgo helps in vascular dementia (where blood flow is compromised) more than in pure Alzheimer's pathology.
Safety and Interactions
Ginkgo is generally well tolerated. The most common side effects are mild: headache, GI upset, dizziness.
Key safety concerns:
This table scrolls horizontally on small screens. Use Tab to focus the table region, then scroll with arrow keys or touch.
| Concern | Guidance |
|---|---|
| Bleeding risk | Mild antiplatelet activity. Caution with warfarin, aspirin, NSAIDs, or before surgery. Stop 2 weeks pre-op. |
| Seizures | Theoretical risk from ginkgotoxin in raw seeds — not in standardized extract. EGb 761 is considered safe. |
| Pregnancy | Insufficient data — avoid. |
| SSRIs/antidepressants | Generally compatible, but monitor for bruising/bleeding. |
Beyond Cognition: Circulation
Ginkgo's circulatory benefits extend beyond the brain:
- Intermittent claudication: Meta-analyses show EGb 761 increases pain-free walking distance by ~33 meters in patients with peripheral arterial disease — comparable to cilostazol but better tolerated.
- Tinnitus: Mixed evidence. Some trials show modest benefit; systematic reviews are inconclusive.
- Altitude sickness: Trials are negative — ginkgo does not prevent AMS.
Related Articles
References
- DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial (2008) — Source
- Napryeyenko O, Borzenko I Ginkgo biloba special extract in dementia with neuropsychiatric features: a randomised, placebo-controlled, double-blind clinical trial (2007) — Source
- Pittler MH, Ernst E Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials (2000) — Source
- Birks J, Grimley Evans J Ginkgo biloba for cognitive impairment and dementia (2009) — Source